Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma

Abstract

Decreasing the frequency of infusions in patients with MF or SS who achieve a response with romidepsin therapy may provide a practical strategy to prolong response.

Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma

“…In our study the modified Severity‐Weighted Assessment Tool was not used, because the study was retrospective and this score was not systematically indicated in the medical records. Our study confirms the existence of long‐term responders (especially in patients with MF) . Although romidepsin seems to be more effective for MF, we did not find any predictive factor for efficacy.…”

TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL‐2R signalling pathway

“…Cutaneous T cell lymphoma (CTCL) is a kind of extranodal non‐Hodgkin T cell lymphoma characterized by the presence of malignant T cells in the skin. Among various forms of CTCLs, mycosis fungoides (MF) and the leukaemic variant Sézary syndrome (SS) are the most prevalent forms of CTCL . Although some induction chemotherapies have been approved for the treatment of CTCL, the responses of many patients are typically short‐lived .…”

“…Among various forms of CTCLs, mycosis fungoides (MF) and the leukaemic variant Sézary syndrome (SS) are the most prevalent forms of CTCL. 1,2 Although some induction chemotherapies have been approved for the treatment of CTCL, the responses of many patients are typically short-lived. 3 Therefore, developing effective chemotherapies for CTCL is extremely urgent.…”

Bexarotene as maintenance treatment after therapies other than skin‐directed therapy in advanced‐stage mycosis fungoides: a pilot study

“…3 Several genetic variants have been found to be strongly associated with risk of melanoma using a candidate gene approach. The aim of our study was to identify, novel CM genetic factors, using all candidate genes encompassed in the MelGene database (www.melgene.org), a comprehensive online database, [3][4][5] by assessing their association in the largest genome wide association study (GWAS) published up to date. 6 Promising signals were selected for replication in UK-Biobank (https://www.ukbioba nk.ac.uk/), a prospective cohort study of 500 000 participants and two independent samples of CM patients and healthy controls from Greece and Cyprus.…”

“…1 In the last 10 years, the need for an MF maintenance treatment has been investigated in the literature, with most of experiences focusing on the early stages 2,3 and a few on the advanced phases. 2,4 Encouraging results on the chances of achieving lasting responses after the treatment have been reported in patients on brentuximab vedotin. 5 However, only a small cohort of patients have been enrolled in clinical trials 5 ; thus, no definitive conclusions can be drawn.…”